
DEPARTMENT OF HEALTH

Minnesota's Experience of Screening for Duchenne Muscular Dystrophy

Duchenne Muscular Dystrophy – Background

- Prevalence 1 in 5,000 live male births
- Onset early childhood, usually 2-3 years of age; almost exclusively affects boys (X-linked recessive)
 - About 1/3 are de novo
- Symptoms
 - First sign is muscle weakness
 - Enlarged calves, waddling gait, and scoliosis
 - Heart and respiratory muscles are affected later
 - Survival into early 30s
- Muscle breakdown leads to elevated creatine kinase (CK) levels



Minnesota Timeline

- August 2021- DMD
 Nominated
- May 2022- Presented at the Advisory Committee and approved to move on to evidence review
- October 2023- Evidence
 Review presented to
 Advisory Committee and
 Vote


- January 2024-Commissioner Packet Review and Approval
- February 24, 2025- MN started Screening for DMD



Laboratory

DMD assay

- Started screening on 2/24/25
- GSP Neonatal Creatine Kinase –MM kit
 - FDA approved kit by Revvity measuring CK-MM levels.
 - Kit is a solid phase, two-site fluoroimmunometric assay based on the direct sandwich technique.
 - Analyte is bound to monoclonal CK-MM specific antibodies.
 - Fluorescence signal is proportional to the analyte concentration in the sample being tested.




Cut-Offs

Established CK-MM cut-offs for DMD assay

| Age at Time of Collection (hours) | Borderline (ng/mL) | Positive (ng/mL) |
|-----------------------------------|--------------------|------------------|
| 0 – 47 | ≥ 1700.0 | NA |
| 48 -71 | ≥ 1500.0 | NA |
| 72 - 167 | ≥ 500.0 | NA |
| ≥ 168 | NA | ≥ 500.0 |

Range 29.2 – 8000 ng/mL

Algorithm



Abnormal Result Interpretations

| _ | |
|------------|--|
| | DUCHENNE MUSCULAR DYSTROPHY |
| | RESULT INTERPRETATION: This newborn |
| | screen shows elevated creatine kinase- |
| Borderline | muscular isoform (CK-MM). This finding |
| | is likely due to muscle injury. Send a |
| | repeat newborn screening specimen at |
| | 14 and 30 days of age. |
| | |

| | DUCHENNE MUSCULAR DYSTROPHY |
|------------|---|
| | RESULT INTERPRETATION: This newborn |
| | screen shows elevated creatine kinase- |
| | muscular isoform (CK-MM). This finding |
| Borderline | is likely due to muscle injury. Collect a |
| | total CK after child is two weeks of age |
| | and fax the results to MDH at 651-215- |
| | 6285. Consult with a neuromuscular |
| | specialist if clinical testing is abnormal. |
| | |
| | |

| | DUCHENNE MUSCULAR DYSTROPHY |
|----------------------------|--|
| | RESULT INTERPRETATION: Multiple |
| | newborn screening specimens, including |
| | the current specimen, have elevated |
| | creatine kinase-muscular isoform (CK- |
| 2 nd Borderline | MM). This finding may indicate muscle |
| | injury or disease, such as Duchenne |
| | muscular dystrophy. Further diagnostic |
| | testing is recommended. Contact a |
| | neuromuscular specialist within one |
| | week. |
| | |
| | |

| | DUCHENNE MUSCULAR DYSTROPHY |
|----------|--|
| | RESULT INTERPRETATION: This specimen |
| | has elevated creatine kinase-muscular |
| | isoform (CK-MM). This finding may |
| Positive | indicate muscle injury or disease, such as |
| | Duchenne muscular dystrophy. Further |
| | diagnostic testing is recommended. |
| | Contact a neuromuscular specialist |
| | within one week. |
| | |

Follow-up

Notification

- Abnormal result notifications made to primary care clinic/provider, midwife, or NICU if baby is admitted
- Provide "just-in-time" education
- Recommend repeat newborn screen total CK after two weeks of age
- Fax screening report, informational fact sheets for both provider and the family, and contact list for neuromuscular specialists




Follow-up

- Persistently elevated CK on repeat newborn screen OR abnormal total CK labs prompts recommendation to consult with neuromuscular specialists within 1 week
- Referral sent to specialists through Natus that gives them access to the screening report and a brief note from us
- Diagnostic form completion is requested



Diagnostic Form – sample data (not all we collect)



| Diagnosis |
|--|
| Clinical diagnosis/outcome: Select from Dropdown |
| If other, specify here: |
| Was diagnosis made prenatally? Unknown No Yes |
| Has the family been notified of the diagnosis? |
| *If yes, MDH long-term follow-up attempts to provide families with resources, when applicable Yes No |
| Intervention/Treatment Information |
| Eligible for commercial exon-skipping therapy? Select from Dropdown |
| |
| Exon skipping therapy received: |
| Exon-skipping therapy name. |
| If other, specify here: |
| Start date: |
| |
| Eligible for gene therapy? Select from Drondown |
| Coloccinom Propadim |
| Gene therapy received? Select from Dropdown |
| Gene therapy name: Select from Dropdown |
| If other, specify here: |
| Start date: |
| |
| Other intervention/treatment: |
| Other medication, specify: Start date: |
| Other, specify: Start date: |
| |
| Intervention/treatment comments: |
| |
| Newborn Screening Program, 601 Robert St. N., St. Paul, MN 55155 |
| Phone (800) 664-7772, Fax (651) 215-6285 REV 07/2021 |

Outcomes

Data Included:

- Newborns with an abnormal DMD screen received by MDH between 2/24/25–8/31/25
- As of 9/22/25

Between February 24 and August 31


0.44%

Had a **borderline DMD** result


- 32,758 newborns screened
- 144 borderline DMD results

94% have follow-up CK testing after a borderline screen

- Most are getting a repeat newborn screen collected and sent to MDH
- Some have opted for diagnostic CK labs instead
- Of the 7 without a repeat, 3 are still pending, 4 have been closed due to lack of response in our follow-up time frame (3 females, 1 male with normal rapid whole exome)



All repeats collected >14 days have been WNL




 For those that have a repeat, they are collected a median of 16 days after birth (1–81 days)

Outcome of repeat screen
Positive
Borderline
WNL


No Infants with DMD have been Identified

- Of those with complete follow-up:
 - 134 (98%) had normal repeat CK testing
 - 3 (2%) have been referred for diagnostic follow-up
 - 2 were referred after positive repeat screen
 - 1 was referred after abnormal clinical CK (instead of NBS)



Birth Injury Associated with Borderline DMD Screen


- 36 (25%) have a **birth injury** noted in NBS notification
- Most are shoulder dystocia
- Almost certainly an underestimate



Few Low Birthweight Newborns Have a Borderline DMD Screen

- Of the newborns with a borderline DMD screen, only 3 were <2,000 grams (LBW)
 - 2% of borderline screens are LBW
 - 0.3% of LBW newborns have borderline result

(3% of our birth population is LBW)



Insights

Cost Considerations

- GSP instrument
- Kit costs
- Staff- Laboratory and/or follow-up
- Laboratory Information Management System Changes
- Molecular Testing

No DMD Case = Unsettling

- One of our three positive cases has presumed presymptomatic limb girdle (unconfirmed as family is electing not to pursue additional testing at this time)
- We don't have a case of DMD yet
 - We would have expected to have about 3 males by this time using prevalence of 1 in 5,000
 - We recently screened our first DMD case (brother with DMD)
 - Initial specimen was borderline for DMD
 - Family refusing follow-up... "has faith and thinks son will not develop disease"

Repeat Newborn Screen Hassles

- Difficulty getting repeat NBS for rural and out of state babies prompted shift
 - Babies born/screened in MN but live in another state cannot get a repeat screen from their state's program if they do not screen for DMD so have to travel back to MN
 - Distance to nearest birth hospital for some more rural families is burdensome vs collecting clinical labs
 - Despite recommendation for repeat NBS, providers ordering clinical CK labs
- Clinical CK labs not so simple either
 - Some providers ordering clinical labs are misinterpreting CK-MB





Questions?